camlipixant + rabeprazole

Camlipixant + rabeprazole is an experimental combination involving **camlipixant**, a selective, orally active small molecule antagonist of the P2X3 purinergic receptor, and **rabeprazole**, an oral proton pump inhibitor that reduces gastric acid secretion. The combination is not an approved drug product but is being studied in clinical pharmacology (drug-drug interaction) trials to assess the effect of proton pump inhibition on camlipixant exposure and safety in healthy participants. **Camlipixant** is in phase 3 development for treatment of refractory chronic cough, acting by selectively inhibiting P2X3 to reduce cough reflex sensitivity while aiming to minimize taste disturbance. **Rabeprazole** is approved for acid-related disorders such as GERD. The combination is relevant for understanding potential pharmacokinetic interplay when camlipixant is administered with acid-suppressive therapy[1][4][6][7].